VAS2870
Based on 20 publication(s) in Google Scholar
VAS2870 is a NADPH oxidase (NOX) inhibitor.
For research use only. We do not sell to patients.
- Purity: 98.79%
- CAS No.: 722456-31-7
- Formula: C18H12N6OS
- Molecular Weight:360.39
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Glucose Metabolism Compound Library
HY-L092
-
Targeted Diversity Library
HY-L099
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) VAS2870
More- Redox Biol. 2023 Jun:62:102679. [Abstract]
- Adv Sci (Weinh). 2025 Jul 21:e07867. [Abstract]
- Sci Adv. 2025 Oct 3;11(40):eady9234. [Abstract]
- Cancer Lett. 2026 Aug 28:654:218589. [Abstract]
- J Transl Med. 2023 Mar 25;21(1):218. [Abstract]
- Free Radic Biol Med. 2022 Mar;181:166-179. [Abstract]
- Free Radic Biol Med. 2022 Mar:182:171-181. [Abstract]
- World J Gastroenterol. 2023 Apr 21;29(15):2294-2309. [Abstract]
- Int Immunopharmacol. 2025 Apr 24:153:114455. [Abstract]
- World J Microbiol Biotechnol. 2023 Aug 21;39(10):284. [Abstract]
- Cancer Med. 2026 May;15(5):e71898. [Abstract]
- Mol Cell Endocrinol. 2020 Dec 1:518:110990. [Abstract]
- Biochem Biophys Res Commun. 2020 Apr 9;524(3):575-581. [Abstract]
- Biochem Biophys Res Commun. 2019 Dec 3;520(2):420-427. [Abstract]
- FASEB Bioadv. 2025 Jul 9;7(7):e70031. [Abstract]
- Exp Ther Med. 2022 Jun 7;24(2):496. [Abstract]
- Research Square Preprint. 2024 Mar 19.
- Research Square Preprint. 2023 Dec 25.
- Universidad De Salamanca. 2023
- Oxid Med Cell Longev. 2022 Feb 27:2022:1193734. [Abstract]
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
IHC
-
In Vivo Efficacy Study
Biological Activity
Target: NADPH oxidase[1]
VAS2870 is effective to suppress PDGF-BB-dependent activation of NADPH oxidase and subsequent production of intracellular ROS. Furthermore, VAS2870 suppresses PDGF-BB-dependent chemotaxis, but not DNA synthesis. Preincubation with VAS2870 (10 and 20 μM) completely abolishes PDGF-mediated NADPH oxidase activation and ROS production. Preincubation with VAS2870 (0.1-20 μM) does not affect PDGF-induced cell cycle progression. However, it abolishes PDGF-dependent chemotaxis of VSMC in a concentration-dependent manner (100% inhibition at 10 μM)[1]. VAS2870 inhibits dose-dependently autocrine increase of cell number in FaO rat hepatoma cells, and almost completely blocked ROS production and thymidine incorporation when used at 25 mM. VAS2870 blocks serum-dependent cell growth of FaO rat hepatoma cells. VAS2870 inhibits proliferation of different human hepatocellular carcinoma (HCC) cell lines. VAS2870 pretreatment enhances TGF-b-mediated apoptosis of FaO rat hepatoma cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 722456-31-7
-
Appearance Solid
-
Molecular Weight 360.39
-
Formula C18H12N6OS
-
Color White to off-white
-
SMILES
C1(N(CC2=CC=CC=C2)N=N3)=C3C(SC4=NC5=C(C=CC=C5)O4)=NC=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
TRIM21 deficiency protects against atrial inflammation and remodeling post myocardial infarction by attenuating oxidative stress. [Abstract]2023 Jun:62:102679. PMID: 36996623 -
Adv Sci (Weinh)
Cancer Cell-Derived Large Extracellular Vesicles Promote Venous Thromboembolism by Activating NETosis Through Delivering CYBA. [Abstract]2025 Jul 21:e07867. PMID: 40686452
VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867. [Abstract]
VAS2870 and MPO-IN-28 significantly reduced the ROS levels of dHL-60.5ab stain VAS2870 and MPO-IN-28 downregulated citH3 expression.
VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867. [Abstract]
VAS2870 and MPO-IN-28 eliminated NETosis.
VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867. [Abstract]
PBS, CC-lEVs, and VAS2870 were continuously injected into C57BL mice via the tail vein for 5 days. Six hours after completing the injections on the 5th day, an iliac vein constriction surgery was performed, followed by collection of plasma and thrombus tissues 48 h post-surgery.
VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867. [Abstract]
Knockout of cyba or use of VAS2870 (2.5 mg/kg, iv, 5 days) markedly inhibited NETosis. H&E staining and confocal microscopy to assess the formation of thrombus and NETosis in the iliac vein across different treatment groups.
VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867. [Abstract]
Knockout of cyba or use of VAS2870 (2.5 mg/kg, iv, 5 days) markedly inhibited VTE. Quantification of thrombus area based on H&E staining among various treatment groups.
-
Sci Adv
Mitochondrial ROS trigger interorganellular signaling and prime ER processes to establish enhanced plant immunity. [Abstract]2025 Oct 3;11(40):eady9234. PMID: 41032619 -
Cancer Lett
Bile acid retention impairs tumoral antigen presentation and intrinsic tumor suppression in MASH-HCC. [Abstract]2026 Aug 28:654:218589. PMID: 42173274 -
J Transl Med
Mitochondrial ROS driven by NOX4 upregulation promotes hepatocellular carcinoma cell survival after incomplete radiofrequency ablation by inducing of mitophagy via Nrf2/PINK1. [Abstract]2023 Mar 25;21(1):218. PMID: 36964576 -
Free Radic Biol Med
Melatonin alleviates PM2.5-triggered macrophage M1 polarization and atherosclerosis via regulating NOX2-mediated oxidative stress homeostasis. [Abstract]2022 Mar;181:166-179. PMID: 35149217 -
Free Radic Biol Med
Silica nanoparticles induce pyroptosis and cardiac hypertrophy via ROS/NLRP3/Caspase-1 pathway. [Abstract]2022 Mar:182:171-181. PMID: 35219847 -
World J Gastroenterol
Ferroptosis inhibition attenuates inflammatory response in mice with acute hypertriglyceridemic pancreatitis. [Abstract]2023 Apr 21;29(15):2294-2309. PMID: 37124891 -
Int Immunopharmacol
Oxidized low-density lipoprotein induced ferroptosis in nucleus pulposus cell contributes to intervertebral disc degeneration via LOX-1/NF-κB/NOX signal. [Abstract]2025 Apr 24:153:114455. PMID: 40112598 -
World J Microbiol Biotechnol
Helicobacter pylori infection induces autophagy via ILK regulation of NOXs-ROS-Nrf2/HO-1-ROS loop. [Abstract]2023 Aug 21;39(10):284. PMID: 37599292 -
Cancer Med
Metronomic Capecitabine Triggers Ferroptosis in Hepatocellular Carcinoma Cells Through Inhibition of TYMS. [Abstract]2026 May;15(5):e71898. PMID: 42108395 -
Mol Cell Endocrinol
2020 Dec 1:518:110990. PMID: 32805334 -
Biochem Biophys Res Commun
Inhibition of LPS-induced Nox2 activation by VAS2870 protects alveolar epithelial cells through eliminating ROS and restoring tight junctions. [Abstract]2020 Apr 9;524(3):575-581. PMID: 32019675
VAS2870 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2020 Apr 9;524(3):575-581. [Abstract]
VAS2870 protects against LPS-induced cell injury through inhibiting Nox2 expression in A549 cells. The expression of Nox2 in control, LPS (150 mg/ml), VAS þ LPS (preincubating cells with 10 mM VAS2870 followed by 150 mg/ml LPS intervention) and VAS (10 mM VAS2870) groups is determined by western blot.
VAS2870 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2020 Apr 9;524(3):575-581. [Abstract]
VAS2870 protects against LPS-induced cell injury through inhibiting Nox2 expression in A549 cells. The expression of Nox2 in control, LPS (150 mg/ml), VAS þ LPS (preincubating cells with 10 mM VAS2870 followed by 150 mg/ml LPS intervention) and VAS (10 mM VAS2870) groups is determined by immunofluorescence labeling (E).
-
Biochem Biophys Res Commun
Toll-like receptor 4 protects against irradiation-induced hematopoietic injury by promoting granulopoiesis and alleviating marrow adipogenesis. [Abstract]2019 Dec 3;520(2):420-427. PMID: 31607480 -
FASEB Bioadv
Endoplasmic Reticulum Stress and Unfolded Protein Response Sensor ERN1 Regulates Organic Dust Induction of Lung Inflammation. [Abstract]2025 Jul 9;7(7):e70031. PMID: 40641847 -
Exp Ther Med
Procyanidin B2 suppresses hyperglycemia-induced renal mesangial cell dysfunction by modulating CAV-1-dependent signaling. [Abstract]2022 Jun 7;24(2):496. PMID: 35837062 -
-
-
-
Oxid Med Cell Longev
Inhibition of the NADPH Oxidase Pathway Reduces Ferroptosis during Septic Renal Injury in Diabetic Mice. [Abstract]2022 Feb 27:2022:1193734. PMID: 35265258
Solvent & Solubility
DMSO : 83.3 mg/mL (231.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
NADPH oxidase activity is measured by lucigenin-enhanced chemiluminescence in a 50 mM phosphate buffer (buffer A), pH 7.0, containing 1 mM EGTA, protease inhibitors, 150 mM sucrose, 5 μM lucigenin, and 250 μM NADPH as substrate. Quiescent cells are starved by serum deprivation for 24 h and treated as indicated, ished twice with ice-cold phosphate buffered saline (PBS), pH 7.4, and harvested. After low spin centrifugation, the pellet is re-suspended in ice-cold buffer A, lacking lucigenin and substrate. Then, the cells are lysed and total protein concentration is determined using a Bradford assay and adjusted to 1 mg/mL. 100 μL aliquots of the protein sample are measured over 6 min in quadruplicates using NADPH (100 μM) as substrate in a scintillation counter. Data are collected at 2 min intervals in order to measure relative changes in NADPH oxidase activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
To test autocrine growth, cells are serum deprived at 40% confluence and, when indicated, the NADPH oxidase inhibitors Apocynin (300 mM) or VAS2870 are added 30 min before serum deprivation and maintained along the experiment. For TGF-b experiments, cells at 70% confluence are serum deprived for 16 h and treated with 2 ng/mL TGF-β in the presence or absence of the EGFR inhibitor AG1478 (20 mM) or VAS2870 (25 mM), which are added 30 min prior to TGF-β[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. ten Freyhaus H, et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res. 2006 Jul 15;71(2):331-41. [Content Brief]
[2]. Sancho P, et al. The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF-β-induced apoptosis of liver tumor cells. Biochem Pharmacol. 2011 Apr 1;81(7):917-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7748 mL | 13.8739 mL | 27.7477 mL | 69.3693 mL |
| 5 mM | 0.5550 mL | 2.7748 mL | 5.5495 mL | 13.8739 mL | |
| 10 mM | 0.2775 mL | 1.3874 mL | 2.7748 mL | 6.9369 mL | |
| 15 mM | 0.1850 mL | 0.9249 mL | 1.8498 mL | 4.6246 mL | |
| 20 mM | 0.1387 mL | 0.6937 mL | 1.3874 mL | 3.4685 mL | |
| 25 mM | 0.1110 mL | 0.5550 mL | 1.1099 mL | 2.7748 mL | |
| 30 mM | 0.0925 mL | 0.4625 mL | 0.9249 mL | 2.3123 mL | |
| 40 mM | 0.0694 mL | 0.3468 mL | 0.6937 mL | 1.7342 mL | |
| 50 mM | 0.0555 mL | 0.2775 mL | 0.5550 mL | 1.3874 mL | |
| 60 mM | 0.0462 mL | 0.2312 mL | 0.4625 mL | 1.1562 mL | |
| 80 mM | 0.0347 mL | 0.1734 mL | 0.3468 mL | 0.8671 mL | |
| 100 mM | 0.0277 mL | 0.1387 mL | 0.2775 mL | 0.6937 mL |
VAS2870 Related Classifications
HY-12804 Related Classifications
Powered by Bioz